Amicus Therapeutics Presents Positive Data From Phase 2 Clinical Trial Of Plicera(TM) For Gaucher Disease (Lufee.com)

Lufee categories

Amicus Therapeutics Presents Positive Data From Phase 2 Clinical Trial Of Plicera(TM) For Gaucher Disease
Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced that the Company will present positive results from a Phase 2 clinical study of Plicera(TM) (isofagomine tartrate) for Gaucher disease at the American College of Medical Genetics (ACMG) Annual Meeting from March 12-16 in Phoenix, AZ.
- Discuss this news

Tell-a-friend about Lufee and this article

You are not logged in to Lufee at this moment. But you can tell a friend about this headline and send him an e-mail with your personal comment.

You still don't have a Lufee Account?

Sign up now and...

Get your personal account for free and sign up today. The sign up process will take you less than 5 minutes.

Signup here for free

Read what other users has to say

Nobody has posted a comment yet. Be the first to leave feedback on this news.

Read other headlines

PTC Therapeutics Announces Publication Of Preclinical Data In PNAS
PTC Therapeutics, Inc. today announced the publication of new preclinical data in the February 12...
Amicus Therapeutics Presents Positive Data From Phase 2 Clinical Trial Of Plicera(TM) For Gaucher Disease
Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered p...
Taurel: Here Come The ‘Targeted Therapeutics’
As the Lilly ceo heads toward retirement, he gave a little talk at the Wharton School of Business...

New users at Lufee